Investigation launched into Emergent’s federal contract; Biden administration weighs policy to reduce nicotine; Beam Therapeutics releases study on CRISPR technology.
Five things for health marketers to know: Tuesday, April 20, 2021
Fewer than 6,000 “breakthrough infections” in U.S.; Biden administration removes restrictions on fetal tissue in research; VP Harris addresses Black maternal health crisis.
Five things for health marketers to know: Monday, April 19, 2021
White House to invest $1.7 billion to fight COVID-19 variants; J&J asked Pfizer and Moderna to study clots together; Relay Therapeutics acquires machine learning firm.
Five things for health marketers to know: Friday, April 16, 2021
Moderna COVID-19 booster shot to be available by fall; Rare clots linked to J&J vaccine may drive vaccine hesitancy; Drug overdose deaths skyrocket during pandemic.
Five things for pharma marketers to know: Wednesday, April 14, 2021
Cavazzoni named director of FDA’s Center for Drug Evaluation and Research; Researchers study if vaccinated people can transmit virus; Sage and Biogen announce promising results in trial for essential tremor.
Five things for pharma marketers to know: Monday, April 12, 2021
COVID-19 double mutant variant cases identified in California; Australia, Italy join U.K. in restricting AstraZeneca vaccine; former Eli Lilly COO joins Thirty Madison as president.
Five things for pharma marketers to know: Thursday, April 8, 2021
Biden says all U.S. adults eligible for vaccine by April 19; FDA extends review of Pfizer skin drug; Novartis makes $1.3 billion deal with Artios for oncology drugs.
Loading...
Culture drives the company
Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.
Want to read more?
Please login or register first to view this content.
